secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0000917520-26-000008
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra Q4 rev -1.7% organic; FY GAAP loss $6.74/sh on $511M goodwill impairment; 2026 adj EPS guidance $2.30-$2.40
--------------------------------------------------------------------------------

- Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.
- FY 2025 revenues $1,635.2M (+1.5% reported, -0.7% organic); GAAP net loss $516.5M ($6.74/sh) includes $511M goodwill impairment.
- Codman Specialty Surgical segment rev $323.3M (+2.7% reported); Tissue Technologies rev $111.6M (-12.8% reported) driven by MediHoney remediation and Integra Skin comp.
- 2026 guidance: revenues $1,662-$1,702M (0.8%-3.3% organic growth); adj EPS $2.30-$2.40; Q1 2026 rev $375-$390M.
- Transformation plan simplifies operating model targeting $25-$30M savings in 2026; net debt $1.6B, leverage 4.5x, liquidity $516M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000008/0000917520-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000008/iart-20260226.htm
  HTML page:      https://secwatch.observer/filing/0000917520-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer